Zoetis EVP Awarded Phantom Stock Units in Routine Compensation Filing
Zoetis Inc.
Subscribe to track ZTS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Zoetis EVP Awarded Phantom Stock Units in Routine Compensation Filing
Company: Zoetis Inc. (ZTS) Form: 4 | Filed: 2025-10-14 Significance: Low
Insider: Driscoll Rimma Title: Executive Vice President | Relationship: Officer
Transaction: • Type: Grant • Security: Phantom Stock Unit • Shares: 149.8609 • Price: $46.71 • Value: $7,000 • Owned After: 5,226.362 units
Key Insight: An EVP received a small grant of phantom stock units as part of the Zoetis Supplemental Savings Plan. This is a routine, non-discretionary compensation event, not an open-market transaction.
Market Context: This type of filing is common for executive compensation and typically does not have a direct impact on market sentiment or stock price.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Zoetis Inc. (ZTS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A routine acquisition of phantom stock units by an executive as part of a company savings plan, with a minimal total value of approximately $7,000.
- Market Impact: Neutral. The transaction is a non-discretionary award and part of a pre-established compensation structure, not indicative of new insider sentiment.
Company Information
| Field | Value |
|---|---|
| Company | Zoetis Inc. |
| Ticker Symbol | ZTS |
| CIK | 0001555280 |
| Industry | PHARMACEUTICAL PREPARATIONS [2834] |
Insider Information
| Field | Value |
|---|---|
| Name | Driscoll Rimma |
| CIK | 0001952575 |
| Title/Position | Executive Vice President |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-10-10 |
| Transaction Code | A (Award) |
| Security Type | Phantom Stock Unit |
| Shares Involved | 149.8609 |
| Price Per Share | $46.71 |
| Total Value | $7,000.00 |
| Shares Owned After | 5226.362 |
| Ownership Type | Direct |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction is an award (Code 'A'), not an open-market purchase reflecting new insider confidence. The value is minimal and the acquisition is part of a standard compensation plan, as noted in the filing's footnotes.
Volume & Sentiment
- Expected Volume Impact: Negligible. This transaction does not involve the open market and will not affect trading volume.
- Sentiment Indicator: Neutral. The market typically disregards small, routine compensation-related grants.
Investment Insights
Positive Market Indicators
- This filing does not present any new positive indicators for the stock.
Risk Factors
- This filing does not present any new risk factors. The transaction is routine.
Key Takeaways
- Routine Compensation: The transaction is an award of phantom stock units acquired under the 'Zoetis Supplemental Savings Plan', confirming its nature as a standard compensation vehicle.
- Immaterial Value: The total transaction value of ~$7,000 is insignificant for both the company and a high-level executive, carrying no weight as a market signal.
- Cash-Settled Derivative: The footnotes clarify these are phantom units that are settled in cash upon separation from service, not common stock. This further detaches the transaction from direct stock ownership implications.
Contextual Analysis
Timing Significance
- There is no apparent timing significance to this transaction. It is likely tied to a regular schedule within the company's savings plan.
Transaction Context
- Footnote 1 explicitly states the units were acquired via the 'Zoetis Supplemental Savings Plan' and are settled in cash. This removes any speculation about the insider's motive, as it is a structured plan acquisition.
- Footnote 2 explains that the phantom stock unit's value is tied to both Zoetis common stock and a small portion of cash-equivalent investments.
Company Context
- Zoetis Inc. operates in the pharmaceutical preparations industry. This filing is a normal course of business for a publicly-traded company's executive compensation program and is unrelated to any specific operational news.
Risk Assessment
Risk Level: Low
Risk Factors
- This filing itself introduces no new investment risks.
- The transaction is non-discretionary and part of a disclosed plan.
Market Considerations
- The market is highly unlikely to react to this filing due to its low value and routine nature.
- Investors should focus on fundamental company performance, earnings reports, and significant insider open-market transactions rather than minor compensation-related filings like this one.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-14 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.